In summary, we report that BTNL2 is a promising cancer immunotherapeutic target, with potential to enhance the efficacy of currently available immunotherapies, and possibly also to offer alternative stand-alone therapy in patients who are resistant to the current cancer immunotherapy. Here, BTNL2 is linked to cancer.